Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT06944392
- Status
- Recruiting
Conditions
- Overactive Bladder (OAB)
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pumpkin Seed Extract — DIETARY_SUPPLEMENTThis is the only intervention
Study Details
This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population.
Key Dates
- Start date
- Apr 11, 2025
- Status verified
- Apr 2026
- Primary completion
- Aug 1, 2026
- Completion
- Oct 1, 2026
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Taking pumpkin seed extractUpon a patient's enrollment into the study and completion of initial study questionnaires, a research team member will provide the patient with a single bottle of pumpkin seed oil extract. Enrolled patients will be instructed to initiate using the pumpkin seed oil extract starting the day they receive the supplement. Patients will start taking one pill by mouth per day for 12 weeks. They will also be advised to contact their urogynecologist for follow-up if they have not noticed improvement in their bladder health following 3 months of use. Furthermore, they will be counseled about not starting new medications or supplements during their time as a study participant and not sharing their pumpkin seed oil extract with anyone else during their time as a study participant.
Primary Outcome Measure
LURN-SI [ Time Frame: 12 weeks ]
Central Contacts
- Julia Geynisman-Tan, MD312-926-9929
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 |
Find similar trials in Chicago, IL
By research site
Related Studies
- PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OABRecruiting · Axonics, Inc. · Chicago, Illinois
- APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in WomenRecruiting · Medstar Health Research Institute · Birmingham, Alabama
- Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)Recruiting · FemPulse Corporation · Beverly Hills, California
- Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in WomenRecruiting · InMode MD Ltd. · Palo Alto, California